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ABSTRACT
The process of transition from childhood to adulthood is
characterised by physical, mental and psychosocial
development. Data on the transition and transfer of care
in adolescents/young adults with coeliac disease (CD) are
scarce. In this paper, 17 physicians from 10 countries
(Sweden, Italy, the USA, Germany, Norway, the
Netherlands, Australia, Britain, Israel and Denmark) and
two representatives from patient organisations
(Association of European Coeliac Societies and the US
Celiac Disease Foundation) examined the literature on
transition from childhood to adulthood in CD. Medline
(Ovid) and EMBASE were searched between 1900 and
September 2015. Evidence in retrieved reports was
evaluated using the Grading of Recommendation
Assessment, Development and Evaluation method. The
current consensus report aims to help healthcare
personnel manage CD in the adolescent and young
adult and provide optimal care and transition into adult
healthcare for patients with this disease. In adolescence,
patients with CD should gradually assume exclusive
responsibility for their care, although parental support is
still important. Dietary adherence and consequences of
non-adherence should be discussed during transition. In
most adolescents and young adults, routine small
intestinal biopsy is not needed to reconfirm a childhood
diagnosis of CD based on European Society for Pediatric
Gastroenterology, Hepatology and Nutrition (ESPGHAN)
or North American Society for Pediatric Gastroenterology,
Hepatology and Nutrition (NASPGHAN) criteria, but a
biopsy may be considered where paediatric diagnostic
criteria have not been fulfilled, such as, in a patient
without biopsy at diagnosis, additional serology
(endomysium antibody) has not been performed to
confirm 10-fold positivity of tissue transglutaminase
antibodies or when a no biopsy strategy has been
adopted in an asymptomatic child.
INTRODUCTION
The Child and Adolescent Health Measurement
Initiative estimates that one million US children
with special health needs make the transition to
adult care every year.1 A large proportion of ado-
lescents/young adults, however, have not been suffi-
ciently prepared for the transfer to adult care.2 3
Coeliac disease (CD)4 is one of the most
common chronic disorders in childhood, and chil-
dren with CD make up an important part of transi-
tion healthcare in the Western world. The overall
prevalence of CD varies from 0.71% in the USA5
to as high as 2.9% in certain age groups in
Sweden.6 Data also suggest that both diagnostic
rates7 8 and incidence of undiagnosed and diag-
nosed CD9 10 are increasing.
Generally, the transition from paediatric to adult
care should be a collaborative process involving
patients, their parents or caregivers, the physician
and the dietician.11 This transition has also been
made a top 10 priority by the American Academy
of Pediatrics11 with dedicated programmes for
patients and professionals (eg, the Bright Future
Programme). There are several transition recom-
mendations for chronic disease,12 13 but very few
for CD,14 and without comment on CD-specific
aspects of different recommendations for diagnos-
tics in childhood15 and adulthood.16 17
In this consensus report, we propose recommen-
dations for the management of CD in adolescents
and young adults, and how to facilitate the transi-
tion to adult healthcare for patients with CD.
METHODS
Seventeen physicians from 10 countries (Sweden,
Israel, Italy, the USA, Germany, Norway, the
Netherlands, Australia, Britain and Denmark) and
2 representatives from patient organisations
(Association of European Coeliac Societies and the
US Celiac Disease Foundation) examined the avail-
able literature on the transition from childhood to
adulthood CD.
Intent and levels of evidence
We carefully weighed all aspects of the childhood
to adulthood transition in relation to CD diagnosis
and management. In conjunction with librarians at
the Karolinska Institute, Sweden, we searched
Medline (Ovid) and EMBASE between 1900 and
September 2015 to identify the most relevant infor-
mation for this review. The following search algo-
rithm was used (“transition of care” or “transition
of management” or “continuity of care”) AND
(“adolescence” or “pediatrics”) AND (“celiac
disease” or “coeliac disease”) and identified 190
references. We also explored the literature on tran-
sitional issues in other paediatric fields and add-
itional relevant literature. The working groups
developed initial recommendations and rated the
quality of evidence and strength according to the
Grading of Recommendation Assessment,
Development and Evaluation method. The quality
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of evidence for each statement was graded as high, moderate or
low (A, B, C).18
Our consensus group consisted of paediatricians (n=8; JFL,
IH, SK, MLM, NR, RS, RT, SH), adult gastroenterologists
(n=6; CC, SEC, PHRG, KEAL, JAM, DSS), two general practi-
tioners (LA, APH), one histopathologist (MMW) and two repre-
sentatives from a patient organisation (MGG, TK).
After an initial review of the literature, we formed working
groups focusing on different topics (see online supplementary
appendix). Each working group worked independently prior to
a first draft created by JFL. All data and opinions were discussed
among all coauthors to reach consensus. The content of this
report was discussed through teleconferencing and at two
gastroenterology meetings (Prague, June 2015; Barcelona,
October 2015). All authors agreed on the conclusions of the
report.
RESULTS
Transfer of responsibility for self-care from the paediatric to
the adolescent patient with CD
Paediatric patients with CD are usually seen by their general
paediatrician and in a specialised centre by a team comprising a
paediatric gastroenterologist, a specialised nurse, a dietician and,
if needed, a social worker or psychologist. In children, the deliv-
ery of care is fundamentally family-centred, whereas in adult-
hood, responsibility becomes autonomous and dependent upon
the needs of individuals.19
Adolescents typically start to seek independence as part of a
structured family environment, but as adults they leave home,
learn how to live with others and assume various responsibilities
(eg, work and societal and financial commitments).20 The transi-
tion process should gradually parallel this evolution of becom-
ing an adult and include an incremental increase in shifting
knowledge and decisions to the adolescent patient with CD.19
The actual transfer may also be triggered by non-age-related
factors, such as pregnancy, marriage, poor dietary adherence,
substance abuse or dropping out from school. While none of
these factors may signal maturity, they may draw the family’s
attention (and that of the family doctor) to the fact that the ado-
lescent is entering adulthood. The physical, mental and psycho-
social development when becoming an adolescent and
ultimately an adult is central to transition. This development
varies between individuals of the same age, and of note, chil-
dren with a chronic disease may develop autonomy later than
their peers.21
Both the family and the adolescent patient should be at the
centre of transition, and the function of the clinician is to
balance the parents’ authority and the need for autonomy in the
adolescent. Many adolescents/young adults have to work hard
to overcome their reliance on their parents. To parents, this
means stepping back and allowing their adolescent children to
make independent decisions. Both overprotection and insuffi-
cient support of the child are undesirable.
In a joint statement,11 three physician organisations suggest
that the physician starts a discussion about transition when the
adolescent is 12–13 years old, develop a transition plan when
the child is 14–15, with the actual transfer taking place at
≥18 years of age. We agree with this timeline, although cultural
and social differences as well as individual patient preferences
mean variations may occur. Transition is a complex process, and
specific aims for transition in adolescents and young adults are
listed in box 1.
Statement: The transition process should gradually parallel
evolution of child to adult and include an incremental increase
in transferring responsibility for self-care to the adolescent
patient with CD. (C)
Recommendation: We recommend to gradually transfer
responsibility of medical care to the adolescent patient with CD.
Growth and puberty
Growth impairment is a known consequence of untreated or
undertreated CD22 23 though many children with short stature
diagnosed with CD in childhood demonstrate good catch-up
growth.24 However, catch-up growth may occur more predict-
ably for those with a delayed bone age at diagnosis and where
growth velocity acceleration during the first year of treatment
for CD is apparent.25 Untreated CD, or CD diagnosed after
attainment of adult height, results in shorter adult height than
seen in healthy controls, particularly among men.26 27 While
the precise pathophysiology may currently be poorly under-
stood, some adolescents and young adults with CD will experi-
ence a delay in pubertal development28 and may continue to
grow and sexually mature beyond the expected age of pubertal
completion.29 This may have implications for emotional matur-
ity, sexual health and menstrual regularity. At the time when
transition is anticipated, the paediatric provider should provide
data regarding the patient’s history of physical development and
should note to the adult provider whether the patient has
achieved his or her final adult height. For those patients who
have experienced significant pubertal delay where the paediatric
provider may be better suited to provide guidance, it may be
advisable to coordinate transition to an adult provider at the
completion of puberty, particularly where other paediatric spe-
cialists such as endocrinologists continue to care for the patient
to manage growth failure. A bone age X-ray may be done for
cases of observed pubertal delay to inform growth expectations
and timing of transition.
Barriers to a successful transition in CD
Several factors inhibit a successful transition; among them is
having an adult healthcare provider without experience of the
Box 1 Specific aims for transition to adult care in
adolescents and young adults with coeliac disease
▸ Encourage maturation of communication and
decision-making skills.
▸ Allow patients to take responsibility for medical
self-management.
▸ Education and counselling of the adolescent/young adult to
manage a gluten-free diet and consequences of
non-adherence.
▸ Recognition and treatment of psychological problems:
discouragement, feeling overwhelmed, anxiety about the
future and complications such as depression and eating
disorders.
▸ Show patients how to become familiar with the healthcare
system, including environmental changes when they legally
become an adult.
▸ Increase disease knowledge and its potential complications.
▸ Help the patient develop good health habits and self-care
skills that encourage autonomy and establish good health
habits.
▸ Address the family’s anxieties or questions.
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relevant disease. The paediatric healthcare provider should
therefore help the adolescent identify a concerned and capable
caregiver for adults.30 A transition programme can only be suc-
cessful if organised with the active participation and interest of
the adult healthcarers,20 who may be a gastroenterologist or a
general practitioner.
One inherent barrier impeding an adolescent’s communica-
tion with a health provider is the fear of being judged. Out of
the fear of being judged by the adult physician, adolescents may
be less likely to ask questions that could reveal a history of non-
adherence with medical recommendations.31 The key here is to
establish a regular communication channel between the adoles-
cent/young adult and the adult physician.
The patients’ impression of their provider influences the like-
lihood of effective communication of health information and
patient concerns. Unsurprisingly, conflict with the healthcare
provider has a negative impact on adherence to therapeutic
regimens.32 33
Cultural distinctions between paediatric and adult providers
have been noted,19 30 where departure from a child to an adult
environment with a greater expectation of patient independence
may deter some families. Families of young adults with a variety
of chronic conditions report relative decrease in support and
availability for advice from their new adult provider.30 Some
patients and parents, therefore, prefer to remain with their
paediatrician. Ensuring that no adolescent drops out at transfer
of care is crucial.11 34
Statement: The patients’ impression of their provider influ-
ences the adherence and communication of health information
and patient concerns. (C)
Recommendation: Healthcare providers are advised to con-
sider that their demeanour is likely to influence patient concerns
as well as the effectiveness of health information.
The actual transfer of care
There are differences between CD and other chronic diseases.
For example, patients do not depend on particular medications
with prescriptions and thus visits to a physician are not obliga-
tory. In fact, many patients believe they have mastered the
gluten-free diet (GFD) and have minimal contact with health-
care. In addition, non-adherence to diet may not cause symp-
toms for years, giving a false sense of security. Therefore,
adolescents/young adults with CD are at risk of ‘medical’
dropout prior to and during transfer.11 34 35 Meanwhile, adult
services expect that their adult patients will be able to care for
themselves and be capable of negotiating the hospital clinical
system. So, clearly there is a need to bridge the gap between the
paediatric and adult services.36 For adult gastroenterologists,
CD is also often perceived as a less serious disease compared
with GI cancer or IBD and knowledge may be limited with
respect to complications, diet, inheritance, extraintestinal mani-
festations and how to monitor patients.
The actual transfer can take many forms. In some settings,
the paediatric and adult gastroenterologists see the patient at the
same visit; in others, paediatric and adult gastroenterologists
meet annually to discuss patients in transition. Optimally, joint
transition clinics with paediatric and adult service clinicians can
be established for information delivery and generating trust in
the new physician.37 Structured transitional models and targeted
education are important and in other chronic diseases38–42 have
been linked to improved care, better health outcome and
improved health-related quality of life (QoL). One path to facili-
tate transition and transfer of care is to create a ‘transition docu-
ment’, which would allow a smooth transfer of individual
medical care data36 (see online supplementary appendix). Such
a transition document should be created by the paediatrician
prior to transfer, and at the minimum, contain details of the
basis for the coeliac diagnosis and information during follow-up
such as serology, anthropometric data, comorbidities and dietary
compliance.
Recommendation: We recommend that the actual transfer
from paediatric to adult care should be structured and include
as the minimum written information on the base of diagnosis,
follow-up, anthropometric data, comorbidities and dietary
compliance.
Communicating with the adolescent/young adult
Adolescents and young adults may have difficulty communicat-
ing with health providers for many reasons. Consequently, pro-
viders should be flexible in their communication styles when
working with young adult patients. At a face-to-face encounter,
it is unclear whether the presence of a parent at the medical
visit may be detrimental or supportive to adolescent/young
adult communication with the provider.31 The presence of a
parent can be helpful if the adolescent has not been prepared
for independent visits.
Traditional medical care for coeliac patients consists of
regular physician visits to evaluate their health, including weight
and height measurements (in children), dietary adherence and
CD-specific serum antibodies.17 Although important, these mea-
sures can be time-consuming. In addition, many patients do not
visit their physician for regular CD follow-up.35 43
Young patients may also have difficulty expressing sensitive
concerns in person to a provider, but may do so more readily by
email.44 Other types of electronic communication, including
videoconferencing, SMS messaging, and online consultations,
have also been tested in paediatric groups with some success.45
Another option can be a self-management e-health coeliac
follow-up independent from time and place limitations.
Research in other disease areas shows that e-health self-
management encourages patients to manage their disease and
improve their physical and psychosocial well-being.46
Issues that need to be discussed during transition/transfer
Several issues may be discussed during the transition period47
(box 2). Some adolescents/young adults may question their diag-
nosis and feel the transition period is a natural point for discuss-
ing how the diagnosis was made and whether re-evaluation is
appropriate. During transition, patients may also realise that
they have a long-term condition that requires monitoring
throughout adult life. They may also become aware that CD is
linked to increased mortality and comorbidity though the excess
risks are generally seen in the first 1–2 years after diagnosis.48–50
Of special importance to the adolescent and young adult with
CD is adherence to a GFD. In Europe, adherence to a GFD by
children and adolescents varies from 44% to 97%,51–55 and
accidental transgressions are common.55 At an early age, a GFD
may have been prescriptively provided by carers at home, with
some involvement of the school. In adolescence, the responsibil-
ity of keeping a GFD must be shared by the child and his or her
parents. Adherence to a GFD can be very difficult,56 57 particu-
larly as the children face new challenges: peer pressure and the
stigma of ‘being different’, school trips and increasing independ-
ence from their parents. Adolescence is recognised to be a
period when adherence is poor and thus potential risk factors
for poor adherence should be recognised.54 The little (and his-
toric) data that are available reveal that increasing adherence can
be maintained by regular follow-up.58
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Adolescents report lower adherence than younger children,
particularly at social events.59 Dietary non-adherence in adoles-
cents is associated with increased disease burden, poorer QoL
and increased physical symptoms.60 Most young people with
CD think that avoiding cancer is the most important reason to
adhere to a GFD.61 62 However, the risk for cancer in CD is
much lower than previously presumed,63–65 and instead, the
risk of osteoporosis66 and adverse pregnancy outcome67 68 may
be bigger issues in individuals with poor adherence. Refractory
CD is very rare in children.69 70
Undiagnosed patients with CD may adopt a high-energy diet
because of malabsorption. If they continue their eating behav-
iour after diagnosis, they risk obesity and metabolic syndrome,
especially the first year after diagnosis.71 Mariani et al61
reported that 72% of Italian adolescents with CD who strictly
adhered to the diet were overweight and consumed an unba-
lanced diet rich in fat and protein, poor in carbohydrate and
deficient in calcium, iron and fibre.
After moving away from home, adolescents/young adults with
CD are responsible for purchasing food and cooking, activities
previously provided by their parents. Financial issues for the
more expensive gluten-free products become more relevant for
adolescents/young adults who now live on a limited budget.
Adolescents attending college or university face both the diffi-
culty of an abrupt transition from home to a dining room situ-
ation with variable provisions for a GFD by their respective
institutions and social pressures in adhering to the diet.72
Statement: Dietary adherence and consequences of non-
adherence are key components for discussion in a transition
setting. (C)
Recommendation: We recommend that dietary adherence and
consequences of non-adherence are key components for discus-
sion in a transition setting.
Current guidelines for coeliac diagnosis
Recently, several guidelines have appeared for CD diagnosis
reflecting the development in diagnosis of CD (eg, better quality
of serological tests and the increased awareness of CD). The
NASPGHAN guidelines (USA) from 200573 clearly address the
questions who to test and how to test using transglutaminase 2
IgA antibody (TG2-IgA) combined with total IgA as a screening
tool, followed by referral to a paediatric gastroenterologist and
biopsy, with the diagnosis based on a histological analysis. More
recently, the ESPGHAN guidelines,15 as well as the British
Society for Paediatric Gastroenterology guidelines for the diag-
nosis of CD,74 advocate TG2-IgA with total IgA (and IgG-based
tests in case of IgA deficiency) as a screening tool. Furthermore,
based on an evidence report,75 in cases with symptoms and very
high TG2-IgA levels (>10× the upper limit of normal (ULN)),
which gives a high likelihood for concurrent enteropathy,76
current ESPGHAN guidelines suggest that in carefully selected
cases a biopsy avoidance strategy may be employed by undertak-
ing further supportive tests (HLA-DQ2 and DQ8 determination
may rule out CD, and the endomysial antibodies (EMAs) test
has a high specificity). If these investigations are consistent with
the suspicion of CD, the diagnosis may be established without a
biopsy after careful discussion with a paediatric gastroenterolo-
gist. Conversely, the adult guidelines from Europe16 and the
USA17 recommend a diagnosis of CD based on TG2-IgA and
with biopsy. The US guidelines17 consider the pre-test probabil-
ity and recommend in populations with high pre-test probability
to use biopsy in conjunction with TG2-IgA. In populations with
a lower pre-test probability, the guidelines suggest waiting for
the TG2-IgA results before performing a biopsy. The British
guidelines in addition use the EMA test for strengthening the
suspicion of CD.
There are good reasons to perform an upper endoscopy with
biopsies in adults with suspected CD (box 3). However, some of
these issues may not apply in children/adolescence. A further
complexity of the CD diagnosis is that the histological analysis
may show variability between histopathologists,77 and use as the
reference standard for the diagnosis of CD has been chal-
lenged.78 79 Therefore, it is important, as recommended by all
guidelines, to take serology, histology and HLA status into
account when there are uncertainties in diagnosis.16
Use of biopsy, CD serology and genetic testing in transition
to adulthood
While duodenal biopsies have been the reference standard for
diagnosis of CD, recently, a selective no biopsy policy has been
Box 3 Reasons for performing a biopsy in the young
adult with a new (suspected) diagnosis of coeliac disease
▸ Antibodies do not have a 100% positive predictive
value.132–134
▸ Patients with either irritable bowel syndrome or Crohn’s
disease of the small bowel can be pseudo-improved by
adhering to a gluten-free diet.135
▸ Baseline histology can allow assessment of severity (degree
of villous atrophy).62 66 87
▸ Many patients need an upper endoscopy anyway because
they have anaemia or other significant symptoms.136
▸ An upper endoscopy is more easily tolerated by adults and
does not typically require general anaesthesia.137
Box 2 Topics that may be discussed during transition in
coeliac disease (CD)
▸ Education on the risk of developing complications despite
being asymptomatic (there can be a long interval between
gluten exposure and the return of symptomatic disease).
▸ A preventive care plan to increase adolescent/young adult
health, even for factors not directly related to CD,122 such as
education about smoking,123 alcohol and drug abuse,124
and the importance of physical exercise.125 Dietary
education that is aimed to avoid deficiencies and to control
weight.126
▸ Medical monitoring with laboratory tests and healthcare
visits according to the management of all chronic
conditions.11
▸ Allocating time and space to discuss with experts about
psychological aspects as CD may influence self-image and
self-esteem12 and interfere with school, education and
work.127 128
▸ Sexuality and fertility. Dietary adherence is especially
important before conception and during pregnancy as
women with untreated CD are more likely to suffer an
adverse pregnancy outcome.67 68 Several large studies have,
however, shown that lifetime fertility is similar in individuals
with and without CD.129–131
▸ The gluten-free diet (see text).
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proposed for some children.15 80–82 In comparison, the policy
adopted by gastroenterologists who care for adult patients uni-
formly requires a biopsy for diagnosis and frequently a
follow-up biopsy to document healing for management and
prognostic information. The no biopsy policy was adopted by
ESPGHAN, but it is not widely accepted in the USA or
Australia. This difference between paediatric and adult gastroen-
terologists may present a topic for discussion in the transition
from paediatric to adult care. Both parties will be interested in
the quality of the diagnosis of CD to attain the best quality of
care. All diagnostic test results must be available to the accepting
physician. Of importance to recognise is that the respective
guidelines may not have been followed by the physician who
made the initial CD diagnosis. The main themes are as follows:
1. Patient diagnosed according to the ‘old’ 1990 ESPGHAN
criteria. Review of the results of serology testing and the
biopsy result will lead to an acceptable diagnosis, allowing
the managing physician to continue the care of the patient.
2. Patient diagnosed according to the ‘new’ 2012 ESPGHAN
criteria.15 Review of the symptoms, results of serology, HLA
status and response to GFD. For levels of TG2-IgA <10×
ULN, biopsy data must be available.
Different scenarios may be envisaged:
1. The child was symptomatic at diagnosis with malabsorption
and the diagnosis based on a TG2-IgA >10× ULN, appro-
priate HLA, positive EMA on a second blood draw and a
good response to a GFD. This diagnosis appears to be of
high quality that should prompt continuing management
with a strict GFD.
2. The child was asymptomatic with, for example, type 1 dia-
betes mellitus (T1DM) and TG2-IgA >10× ULN, appropri-
ate HLA and no biopsy. A single positive tTG IgA test may
have been obtained without a second blood draw, confirming
a positive tTG or EMA. In this setting, it is necessary to con-
sider whether there may be a temporary coeliac autoimmun-
ity as has been seen in children and adults.83 84 The 2012
ESPGHAN criteria are not met in that these criteria do not
accept a definitive diagnosis of CD without a biopsy in
asymptomatic at-risk groups (a biopsy may be suggested after
a gluten load). We urge caution in accepting a diagnosis
where diagnostic criteria, as outlined by paediatric guidelines
in Europe or North America, have not been fulfilled.
The serological diagnosis of CD is dependent on the quality of
the assay employed. For TG2-IgA, the majority of the tests are
based on ELISA and eminently suited for assay quality control
measures. EMA testing is based on immune fluorescence and
with an operator-dependent read-out with possibilities for vari-
ability. Yet, EMA testing is the assay with the highest specificity.75
As stated in the ESPGHAN diagnostic guideline, to rely on ser-
ology, the tests have to be subject to continuous participation in
control measures (such as the National External Quality
Assurance Scheme (NEQUAS) initiative in Europe). In non-
European countries, significant laboratory variability may occur
and whether these cut-offs are valid in countries such as the USA
are yet to be confirmed. A diagnosis made according to the
ESPGHAN guidelines outside of Europe should be considered in
the context of this potential uncertainty.85
The histological evaluation may also be indeterminate78 86
and transition into adult care could be a convenient time for
re-evaluation, even when the initial diagnosis is definitive.
Table 1 is an overview of differences in the use of histology for
diagnostic purposes in children and adults.
Persistent mucosal lesions are common in adults with CD,
despite normalisation of serologies.87 Concomitant with these
lesions are augmented risks of morbidity such as lymphoma62
and certain fractures.66 Whereas these risks may be lower in
children,69 and refractory CD and consequently enteropathy
associated t-cell lymphoma (EATL) is extremely rare in subjects
with CD diagnosed in and treated since childhood, adolescents
and young adults with CD may have greater difficulty with
dietary adherence, whether accidental or intentional.59 88 Early
identification of such risks may thwart future adverse outcomes
and identify those in need of greater surveillance.
Also important is the procedure adopted for transitional
follow-up. If the existing diagnostic guidelines have not been met
and the diagnosis needs re-evaluation, a new diagnostic approach
should be instituted. Serology and histology may be part of this
approach.16 However, undertaking duodenal biopsies while on a
GFD may be uninformative, except for ruling out differential
diagnosis and to confirm mucosal healing. After transition, care
will be determined dependent upon the results of nutritional,
serological, genetic and dietary assessment.16 There are four indi-
cations for performing a biopsy before or after transition to adult
care in some settings with a gluten challenge:
Table 1 Histology in children and adults with suspected coeliac disease (CD)
Children Adults
Is a biopsy necessary for
diagnosis?
Dependent on TG2 level, HLA status—if anti-TG2 titres are high
(>10 times the upper limit of normal), the ESPGHAN guidelines
have an option to diagnose CD without duodenal biopsies by
applying a strict protocol with further laboratory tests.15
Recommendation for biopsy—all guidelines emphasise the combined
use of biopsy and serological analyses for diagnosis.16 17 138 139
However, in low-resource countries, a positive TG2 with symptom
improvement on a GFD may be considered sufficient for
diagnosis.138 139
How many biopsies? And
where from?
4–6 including 2 from bulb, as focality was present in 18%,
patchiness in 53% and at least 1 normal biopsy fragment was
present in 36% of the cases. Sometimes, changes compatible
with CD are only seen in the bulb,140 11% of patients show only
duodenal bulb involvement, and also bulb sparing, so both
should be taken.141
At least four, including bulb biopsy.16 141
Adherence to guidelines for
biopsy?
In those without histological evidence of CD, fewer biopsies are
obtained with none documented from the bulb. Failure to take
the recommended number of biopsies could result in some missed
cases of CD.142
Adherence to submitting ≥4 specimens is low in the USA.
Adherence yields a doubling of the diagnostic rate of CD.143
Intraepithelial lymphocytes/100
enterocytes. What is the cut-off
count?
Normal architecture with increased IELs is considered non-specific
in paediatric guidelines.15
Normal architecture with ≥25 IELs/100 enterocytes has been
validated as a cut-off point in adults.16 144
GFD, gluten-free diet; IEL, intraepithelial lymphocyte; TG2, transglutaminase 2.
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1. if the existing guidelines have not been met;
2. the adolescent has ceased a GFD because he or she doubts
the diagnosis;
3. the patient or the physician requires documentation of
healing;
4. the presence of symptoms suggests active CD or another
diagnosis.
The potential contribution of genetics in ruling out CD in
suspect or insufficiently diagnosed cases is important. CD is
strongly associated with the HLA-DQ2 and HLA-DQ8 geno-
types.89 While HLA-DQ2 or DQ8 occurs in >99% of people
with CD, it is found in ∼30% of the general population, and
therefore, a positive genetic test does not confirm a CD
diagnosis.90
Statement: In adolescents and young adults, biopsy to recon-
firm a childhood diagnosis of CD may be considered when the
10-fold positive tissue transglutaminase antibody result has not
been confirmed by positive EMA in a second serology at the
time of diagnosis or when the ESPGHAN diagnostic criteria
have not been met in a child without duodenal biopsies.
Biopsies may also be relevant when the adolescent has ceased a
GFD because he or she doubts the diagnosis; the patient or the
physician requires documentation of healing; and the presence
of symptoms suggests active CD. (C)
Recommendation: We recommend that in adolescents and
young adults, routine small intestinal biopsy is not required to
reconfirm a childhood diagnosis of CD when the diagnosis has
been made according to ESPGHAN or NASPGHAN criteria.
Statement: HLA testing can be used to rule out CD in unclear
cases. (B)
Recommendation: We recommend testing for HLA-DQ2 and
HLA-DQ8 genotypes in unclear cases.
The gluten challenge
A gluten challenge after transfer to adult care is normally not
needed if diagnostic criteria have been followed, including chil-
dren diagnosed younger than 2 years of age.91 A gluten chal-
lenge is indicated when the primary diagnosis of CD was not
performed according to standards and guidelines.15 A second
circumstance when a gluten challenge is applicable is when the
patient requests proof of the diagnosis, even though the initial
diagnosis was performed according to the current standards.
There are no well-established rules in a gluten challenge. The
clinical tolerability and the time to relapse vary between
patients, but traditionally a 3 months’ challenge with moderate
to high amounts of gluten has been advocated,92 keeping in
mind that an enteropathy may occur after an extended period
of time.93 Before gluten challenge, serology for CD-specific
autoantibodies should be performed (duodenal biopsies should
preferentially be obtained as well). An increase in CD-specific
serum autoantibodies follows histological change. Therefore, if
the patient remains asymptomatic, the biopsies should be per-
formed when serology is positive.
Non-coeliac gluten sensitivity in children
Non-coeliac gluten sensitivity (NCGS) is a differential diagnosis
to consider in patients with symptoms of CD, but TG2-IgA and
EMA are negative and the histology is normal or near normal
(only lymphocytic duodenosis is accepted16). The genotypes
HLA-DQ2/DQ8 may or may not be present. The distinction
between wheat allergies with negative IgE antibodies may be dif-
ficult. In children, circumstantial evidence suggests that a pro-
portion of children suspected of CD, but with the characteristics
mentioned above, may have NCGS.94
However, to our knowledge, no study of blinded, placebo-
controlled food challenges has been performed in children with
gastroenterological symptoms of NCGS. The prevalence of
NCGS in children is still unclear, and further studies are
needed.95 96
Statement: There is as yet no reliable prevalence data on
NCGS in children. (C)
Recommendation: We recommend that the diagnosis of
NCGS in children/adolescents is not made on a regular basis,
but awaits further documentation.
Follow-up
Follow-up of patients with CD is advocated to ensure dietary
adherence, prevent or detect complications or associated condi-
tions including autoimmune thyroid disease, and promote optimal
health.16 97 98 Data, though limited, suggest continued follow-up
improves dietary adherence, whereas lack of regular follow-up
seems to be a particular problem for the phase of transition
between paediatric and adult care.35 54 58 99 100 Based on expert
opinion, all paediatric patients should be seen at 3–6-month inter-
vals for the first year after diagnosis. Once symptoms have resolved
and serological tests for CD have normalised, an annual follow-up
visit is recommended. This recommendation is in line with that for
adult patients with CD.16
CD is associated with fracture risk,101 102 predominantly
before treatment or in the setting of non-adherence to GFD.103
Bone mineral density is frequently depressed in both children104
and adults105 with CD at the time of diagnosis, and deficits
have been shown to correlate with degree of histological sever-
ity.106 The vast majority of children recover from bone mineral
density abnormalities following appropriate therapy.107 Thus,
dual-energy X-ray absorptiometry should only be considered for
young adults at high risk (eg, known history of low-energy bone
fractures, dietary non-adherence, established persistent villous
atrophy or low body mass index (<20 kg/m2)).
A subset of patients with CD suffer from other diseases of
autoimmune pathogenesis such as T1DM108 and thyroid
disease.50 CD is more often seen in patients with Down’s syn-
drome.109 Some of these patients may present specific problems
in the transition phase and guidelines have been published on
transition in T1DM and Down’s syndrome.13 110 As far as CD
is concerned, in patients with T1DM, the GFD may represent a
special challenge as diet is already an issue in patients with
T1DM.
Dermatitis herpetiformis111 112 is a pruritic skin condition
strongly linked to CD. Adolescents and young adults with
dermatitis herpetiformis should be aware that medical treatment
with dapsone will remedy itch but will have no influence on
small intestinal inflammation. Hence, a strict GFD is crucial for
this group of patients.
Primary care involvement
In many countries, adolescents leaving paediatric care are often
cared for by a general practitioner rather than by an adult
gastroenterologist. Primary care physicians (PCPs) are then also
responsible for the healthcare during and after transition. In
adults, PCPs may take a major role in care, dependent upon
management care programmes and the availability of skilled per-
sonnel and local practice.
Some adolescent/young adult patients are also referred to
primary care when they are considered healthy after diagnostic
work-up information and initial follow-up in secondary care
(either with a paediatrician or an adult gastroenterologist).
Primary care may also be a suitable care provider if adequate
Ludvigsson JF, et al. Gut 2016;65:1242–1251. doi:10.1136/gutjnl-2016-311574 1247
Guidelines
group.bmj.com on September 1, 2017 - Published by http://gut.bmj.com/Downloaded from 
resources in terms of personnel skills and laboratory facilities
are sufficient for long-term follow-up. In settings where the
PCP has access to upper endoscopies with biopsies, the adoles-
cent/young adult be solely cared for by the PCP, provided that
relevant skills, a dietician with expertise is available, and that
the care results in good self-reported health and normalised
laboratory data. Whenever the patient’s follow-up is in primary
care, a management plan should be followed.16 When seeing an
adolescent/young adult with CD, the PCP also has to consider
an increased risk for other autoimmune diseases.50 108 113–115
Statement: The PCP is often the care provider who is closest
to the adult patient with CD. (C)
Recommendation: Primary care may be a suitable care pro-
vider if adequate personnel skills and laboratory facilities are
sufficient for long-term follow-up, and this may depend on local
practice.
Economic issues
The cost of gluten-free products is often substantially higher
than that of gluten-containing products.116–118 Different eco-
nomic models are used to compensate patients with CD, with
tax deduction used in parts of Europe (eg, Germany) and North
America,119 and prescriptions for GFD in many European coun-
tries. Prescriptions may, however, only apply to children and in,
for example, Austria, Estonia, Finland, Hungary, Spain and
Ukraine, adults with CD receive no government support for
extra costs (personal communication, T Koltai, 17 February
2016). While in Italy there are no requirements for the quality
of food prescribed, the coeliac society in the UK restricts the
prescribed list to essential products, excluding gluten-free foods
considered ‘unhealthy’ such as gluten-free snacks and desserts.
In those countries where prescription and rebates on GFD are
restricted to children, becoming an adult will incur extra costs
of GFD, potentially having a negative impact on dietary
adherence.
The cost of healthcare in the transitional period between ado-
lescence and adulthood will vary according to the country of
residence. Indeed, in some countries one in three young adults
has unmet health needs because of cost.120 Special issues arise
in the USA with its hybrid healthcare system. Poor children may
be covered by Medicaid or Children’s Health Insurance
Program. In the USA, the Patient Protection and Affordable
Care Act (2010) included a provision for a child to remain
under his or her parents’ insurance plan until age 26. This act
also prevented denial of coverage based on the presence of a
chronic condition. However, the parents’ insurance may be
inadequate to make the needed care affordable.
DISCUSSION
Seventeen physicians and two representatives from CD patient
organisations wrote this consensus report after reviewing the lit-
erature on the transition of CD care from childhood to
adulthood.
The strengths of our paper lie in the systematic literature
search and the involvement of patient organisation representa-
tives. However, we acknowledge several weaknesses, including a
low level of evidence, and we are not aware of any randomised
trials on transition in CD. Despite the lack of CD-specific evi-
dence, we have tried to make statements and recommendations,
sometimes based on inference from data in other chronic dis-
eases and sometimes on our own pooled clinical experience. We
have listed several recommendations of care adding to more
general recommendations of diagnostics and management in
CD.15–17 Still, we understand that countries, and thereby the
conditions for care of delivery, differ. We also recognise that
resource limitations will hinder some providers from offering
joint clinics and follow-up as suggested.
We believe that we offer a working approach to adolescents
and young adults who were once diagnosed without a small
intestinal biopsy15 and now enter adult healthcare where biopsy
is still generally recommended to diagnose the condition.16 17
That said, we recognise that there is international variation of
practice based on social practice and that individual patient pre-
ferences may also influence the transition process.
We recommend that the diagnosis be re-evaluated only when
made outside current ESPGHAN or NASPGHAN recommenda-
tions or when the patient questions his/her diagnosis. That does
not mean that a paediatric CD diagnosis is more erroneous than
a diagnosis made by an adult gastroenterologist.
The implementation of a systematic transition policy in CD
has been limited by a lack of clinical guidelines based on
outcome-related research and clear and consistent definitions.4 In
the absence of solid evidence, different models of transition will
be likely developed locally. We still do not know if a standardised
protocol-driven transition process is superior to a process that
varies both nationally and internally. These differences will con-
tribute to the differences that exist between the different health-
care systems. Models of transition42 will eventually need to be
evaluated in randomised controlled trials with clear patient
outcome measures. It is crucial to know to what extent a well-
structured and planned transition will influence adherence to a
GFD, which in CD is imperative for restoration of health and
well-being. This aspect will depend on the prevalence and quality
of complications, as well as on health-related QoL.57 121
Socio-economic effectiveness and outcomes of care of the differ-
ent models should also be carefully evaluated. Further studies are
needed to identify and remove barriers20 to transition.
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